Tags

Type your tag names separated by a space and hit enter

Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
Expert Opin Pharmacother 2003; 4(10):1857-60EO

Abstract

Over stimulation of the NMDA receptor by glutamate has long been considered to have a role in Alzheimer's disease (AD). Memantine, a non-competitive antagonist of NMDA receptors, has recently been tested in moderate-to-severe AD. At 28 weeks, there was a small significant mean difference of 0.3 in favour of memantine, showing benefit in the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) global score. The other primary efficacy variable was the Alzheimer's disease Cooperative Study Activities of Daily Living Inventory, modified for more severe dementia (ADCS-ADL-sev) and there was significantly less deterioration in the ADCSADL-sev score in the memantine group than in the placebo group (2.1 versus 3.4, respectively). As there are no drugs commonly used for their effectiveness in moderate-to-severe AD, any drug that causes a benefit, however small, as memantine has been shown to do in this trial, represents a breakthrough.

Authors+Show Affiliations

Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s_doggrell@yahoo.co

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14521495

Citation

Doggrell, Sheila. "Is Memantine a Breakthrough in the Treatment of Moderate-to-severe Alzheimer's Disease?" Expert Opinion On Pharmacotherapy, vol. 4, no. 10, 2003, pp. 1857-60.
Doggrell S. Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease? Expert Opin Pharmacother. 2003;4(10):1857-60.
Doggrell, S. (2003). Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease? Expert Opinion On Pharmacotherapy, 4(10), pp. 1857-60.
Doggrell S. Is Memantine a Breakthrough in the Treatment of Moderate-to-severe Alzheimer's Disease. Expert Opin Pharmacother. 2003;4(10):1857-60. PubMed PMID: 14521495.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease? A1 - Doggrell,Sheila, PY - 2003/10/3/pubmed PY - 2003/12/19/medline PY - 2003/10/3/entrez SP - 1857 EP - 60 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 4 IS - 10 N2 - Over stimulation of the NMDA receptor by glutamate has long been considered to have a role in Alzheimer's disease (AD). Memantine, a non-competitive antagonist of NMDA receptors, has recently been tested in moderate-to-severe AD. At 28 weeks, there was a small significant mean difference of 0.3 in favour of memantine, showing benefit in the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) global score. The other primary efficacy variable was the Alzheimer's disease Cooperative Study Activities of Daily Living Inventory, modified for more severe dementia (ADCS-ADL-sev) and there was significantly less deterioration in the ADCSADL-sev score in the memantine group than in the placebo group (2.1 versus 3.4, respectively). As there are no drugs commonly used for their effectiveness in moderate-to-severe AD, any drug that causes a benefit, however small, as memantine has been shown to do in this trial, represents a breakthrough. SN - 1465-6566 UR - https://www.unboundmedicine.com/medline/citation/14521495/Is_memantine_a_breakthrough_in_the_treatment_of_moderate_to_severe_Alzheimer's_disease L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.4.10.1857 DB - PRIME DP - Unbound Medicine ER -